Abstract. The effect of nitric oxide (NO) on plasma fibrinogen was investigated by treating mice with oral N G -nitro-L-arginine-methyl ester (L-NAME), a non-selective NO synthase (NOS) inhibitor. Treatment with L-NAME significantly increased the concentration of plasma fibrinogen and hepatic expression of the α-and β-chains of fibrinogen, whereas plasma NO 2 − level and hepatic expression of endothelial NOS (eNOS) mRNA were significantly decreased. These results suggest that L-NAME treatment can increase plasma fibrinogen levels via an increase in expression of fibrinogen mRNA in the liver, and NO may be involved in plasma fibrinogen increase.
Nitric oxide (NO) plays an important role in the regulation of vascular tone, is a critical regulator of vascular remodeling, and also inhibits atherosclerosis (1, 2) . Increased plasma fibrinogen concentrations may contribute to the development of atherosclerosis and ischemic cardiovascular disease (3, 4) via effects on blood viscosity, platelet aggregation, and fibrin deposition. Systemic administration of N G -nitro-L-argininemethyl ester (L-NAME) resulted in a 2-to 3-fold increase in platelet adhesion to the balloon-injured vessel wall, suggesting it may inhibit blood flow in the injured artery (5) . In contrast, administration of Larginine reduces neointimal formation in balloon-treated arteries (6) . The aim of the present study was to examine the potential role of NO in the regulation of plasma fibrinogen concentrations using L-NAME and L-arginine to modulate NO levels in mice.
Male C57BL / 6J mice, 5-weeks-old, were purchased from Sankyo Labo Service Co. (Tokyo) and fed a standard mouse chow and water. Mice were divided into 5 groups of 8 each and were treated with either saline; L-NAME (Sigma-Aldrich Co., St. Louis, MO, USA) at 100, 300, or 500 mg / kg per day; or L-arginine (SigmaAldrich) at 500 mg / kg per day. After oral administration for three days, blood specimens were taken from the inferior vena cava under pentobarbital anesthesia and mixed with 3.2% sodium citrate solution in a volume ratio of 9:1. All procedures were performed according to the principles for the care and use of experimental laboratory animals of Showa University.
Plasma fibrinogen levels were measured as previously reported (7) . To determine hepatic mRNA levels of α-, β-, and γ-fibrinogen and prothrombin, the liver tissue from each mouse was homogenized with Isogen (Nippon Gene, Tokyo) on ice for total RNA extraction. Sense and antisense primers for mouse fibrinogen, prothrombin, and endothelial NOS (eNOS) genes were designed using GENETIX ® Ver.6.1.0. (GENETYX Co., Tokyo) for PCR primer optimization using the published complete cDNA sequence for mouse. The sense-primer sequence for β-actin was 5'-TTGTTACCAACTGGG ACGACATGG-3' and the antisense-primer was 5'-GATCTTGATCTTCATGGTGCTAGG-3'. The senseprimer sequence for α-fibrinogen was 5'-GTCTGATG GCACTGGAGACTGG-3' and the antisense-primer was 5'-TTCGCTTCCTGCCTCGTCTGCC-3'. The senseprimer sequence for β-fibrinogen was 5'-TGTCAGCT GCAACATTCCAGTG-3' and the antisense-primer was 5'-GAGTACCACGATCCCTTCCAG-3'. The senseprimer sequence for γ-fibrinogen was 5'-GTCCACAAT TCCATATGCACTGAG-3' and the antisense primer was 5'-CTTCATGGTGGTTTCCTTGATAG-3'. The sense-primer sequence for prothrombin was 5'-CAAGC ATTCCCGAACCAGATATG-3' and the antisenseprimer was 5'-TCCTCGCTTGGTGTCATTCACC-3'. The sense-primer for eNOS was 5'-TTCCGGCTGCC ACCTGATCCTAA-3' and the antisense-primer was 5'-AACATATGTCCTTGCTCAAGGCA-3'. The RT reaction was performed in a 50-µl reaction mixture containing 2.5 µg of total liver RNA, 250 U moloney murine leukemia virus (M-MLV) reverse transcriptase (ReverTra Ace ® ; TOYOBO Co., Ltd., Osaka), 62.5 pM random primer, and all four deoxynucleotide phosphates (dNTPs: 10 mM each) in PCR buffer, pH 8.3, consisting of 75 mM KCl, 50 mM Tris-HCl, 3 mM MgCl 2 , and 50 U RNase inhibitor. Samples were incubated at 42°C for 20 min, heated at 99°C for 5 min, and then the RT reaction was stopped. cDNA was amplified in 25 µl of PCR reaction mixture containing 5 µl cDNA, 0.4 µM of each primer, 2 µl of each dNTP (1 mM), 1 U AmpliTaq DNA polymerase (Sigma-Aldrich), and PCR buffer of 50 mM KCl, 10 mM Tris-HCl (pH 8.3), and 1.5 mM MgCl 2 . Figure 1 shows the standard concentration curves for β-actin, prothrombin, eNOS, and α-, β-, and γ-fibrinogen. PCR products for β-actin and target RNA were quantified by measurement of fluorescence intensity. PCR of α-chain fibrinogen mRNA was performed with a Takara PCR thermal cycler (Takara Shuzo, Tokyo) for 21 cycles at 95°C for 60 s, 60°C for 60 s, and 72°C for 120 s. For β-chain fibrinogen mRNA, we used 22 cycles of 95°C for 60 s, 60°C for 60 s, and 72°C for 120 s; for γ-chain fibrinogen mRNA, 21 (ANOVA) following by the Tukey's post-hoc test was performed to assess differences between the relevant control and each experimental group. Differences with P values of less than 0.05 were considered to be significant.
A previous study showed that treatment for 7 days with L-NAME elevated plasma fibrinogen concentration in rats, but that treatment for 4 weeks with L-NAME did not cause chronic hyperfibrinogemia (8, 9) . Here, plasma fibrinogen concentrations were significantly increased in mice treated with L-NAME for only 3 days (333.9 ± 15.6 mg / dl at 300 mg / kg per day and 334.3 ± 21.3 mg / dl at 500 mg / kg per day) compared to controls (237.0 ± 7.9 mg / dl), while they were significantly decreased in mice treated with L-arginine compared to 500 mg / kg L-NAME (Fig. 2) . Treatment with 500 mg / kg L-NAME lead to a significant decrease in plasma NO 2 − levels (data not shown), as determined by NO 2 − / NO 3 − assay kit-F (Wako Pure Chemical Ind. Ltd., Osaka). The hepatic expression of eNOS mRNA was also significantly decreased in mice treated with 500 mg / kg L-NAME (54.8 ± 8.1%) compared to controls and increased significantly in arginine-treated mice (108.4 ± 24.4%) compared to 500 mg / kg L-NAME. Therefore, it is possible to say that 500 mg / kg L-NAME inhibits the hepatic expression of eNOS mRNA, decreases plasma NO level and then increases plasma fibrinogen concentration. We also investigated plasma levels of interleukin 6, a marker of acute vascular inflammation (10) , and aspartate aminotransferase, a marker of cell membrane injury, using commercially available kits, but found no differences between control and treated animals (data not shown).
We previously reported that hepatic mRNA expression of each of the fibrinogen chains was significantly enhanced with an increase in plasma fibrinogen (11) . The effect of L-NAME on the hepatic expression of α-, β-, and γ-fibrinogen is not known. Treatment of mice with 500 mg / kg of L-NAME led to a significant increase in the levels of expression of hepatic α-fibrinogen mRNA (142.1 ± 18.5%) and β-fibrinogen mRNA (131.9 ± 7.1%) (Fig. 3) . In contrast, treatment with 500 mg / kg of L-arginine significantly decreased hepatic α-fibrinogen mRNA (64.2 ± 3.3%), β-fibrinogen mRNA (90 ± 4.2%), and γ-fibrinogen mRNA (76.6 ± 4.4%) compared to 500 mg / kg L-NAME (Fig. 3) . The hepatic expression of prothrombin mRNA was also significantly increased in mice treated with 500 mg / kg L-NAME (128.5 ± 9.7%) compared to controls and significantly decreased in arginine-treated mice (75.2 ± 3.9%) compared to 500 mg / kg L-NAME (Fig. 3) .
This study therefore showed that short-term treatment with high-dose L-NAME significantly increased plasma fibrinogen concentration, with an increase in the hepatic expression of mRNA of the α-and β-fibrinogen chains, whereas treatment with L-arginine led to a mild decrease in the hepatic mRNA of α-, β-, and γ-fibrinogen expression. The initial steps in fibrinogen assembly involve the formation of α-γ and β-γ dimers bound by disulfide bonds. Then a β-chain or α-chain is added to each dimer and α-β-γ half molecules are formed. Finally, two halfmolecules dimerize and become linked by five disulfide bonds to form the intact fibrinogen molecule (12). Roy et al. suggested that β-fibrinogen production is the rate limiting step of fibrinogen production (13) , and therefore, the overexpression of β-fibrinogen in mice treated with 500 mg / kg L-NAME that we observed may have led to an increase in plasma fibrinogen. In addition, the significant increase in expression of prothrombin mRNA in mice treated with 500 mg / kg L-NAME may also have increased the thrombotic risk (14) , while Larginine may have protected against thrombosis due to the decrease in hepatic mRNA expression of α-, β-, and γ-fibrinogen and prothrombin. A diminished endothelium-derived NO has been considered to play an important role in the atherogenic processes due to the endothelial dysfunction such as vasoconstruction (15) . In this paper, we showed the possibility of NO involvement in the increase in plasma fibrinogen that enhanced the platelet aggregation, blood viscosity, and fibrin deposition (3).
In conclusion, these results suggest that the inhibition of NO production by treatment with high dose L-NAME, a non-selective NO synthase inhibitor, may increase the Fig. 2 . Plasma fibrinogen levels in mice treated with 100, 300, and 500 mg/kg per day of L-NAME and with 500 mg/kg per day of Larginine for three days. Each column represents the mean ± S.E.M. for 8 mice /group. *P<0.05 vs control salin-treated mice. ## P<0.01 vsrisk of cardiovascular disease, via increased hepatic mRNA expression of α-and β-fibrinogen chains, leading to increased plasma fibrinogen levels, and increased prothrombin levels.
